Search

Christian B Beaudry

from Phoenix, AZ
Age ~52
Get Report
Related to:
Craig D Martin, 52Bella Beaudry
Connected to:
Billy Beaudry, 46Bruce D Beaudry, 70Christopher J Beaudry, 57Craig S Beaudry, 46Deborah K Beaudry, 68Dustin Beaudry, 42Jean J Beaudry, 63Joy S Beaudry, 71Katie L Beaudry, 38Kyle J Beaudry, 43

Christian Beaudry Phones & Addresses

  • 1627 W Burnside Trl, Phoenix, AZ 85085 (623) 332-5792
  • Litchfield Pk, AZ
  • Scottsdale, AZ
  • 1627 W Burnside Trl, Phoenix, AZ 85085 (623) 242-9286

Work

Position: Clerical/White Collar

Education

Degree: High school graduate or higher

Specialities

Employment and labour • Infrastructure, mining and commodities • Technology and innovation • Arbitration of disputes (Canada) • Employment and labour (Canada) • Language legislation (Canada) • Managing labour relations and union campaigns (Canada) • Occupational health and safety and workers' compensation (workplace safety and insurance) (Canada) • Outsourcing health and safety (Canada) • Training (Canada)

Professional Records

Lawyers & Attorneys

Christian Beaudry Photo 1

Christian Beaudry - Lawyer

View page
Specialties:
Employment and labour
Infrastructure, mining and commodities
Technology and innovation
Arbitration of disputes (Canada)
Employment and labour (Canada)
Language legislation (Canada)
Managing labour relations and union campaigns (Canada)
Occupational health and safety and workers' compensation (workplace safety and insurance) (Canada)
Outsourcing health and safety (Canada)
Training (Canada)
ISLN:
909168542
Admitted:
1981
Law School:
Université de Montréal, LL.L., 1980

Resumes

Resumes

Christian Beaudry Photo 2

Founder And President

View page
Location:
1627 west Burnside Trl, Phoenix, AZ 85085
Industry:
Biotechnology
Work:
Amnio Technology Jan 2015 - Oct 2018
Chief Scientific Officer
Equigenex Jan 2015 - Oct 2018
Founder and President
Aluta Biosciences Jan 2015 - Oct 2018
Co-Founder
Equus Innovations Jan 2015 - Oct 2018
Co-Founder, Chief Scientific Officer, Chief Operating Officer and Member, Board of Directors
Pinnacle Transplant Technologies Feb 2013 - Jan 2015
Director of Operations
Education:
American Academy of Regenerative Medicine 2016 - 2016
University of Phoenix 2005 - 2007
Master of Business Administration, Masters University of Quebec 1996 - 1999
Bachelors, Bachelor of Science, Medical Biology
Skills:
Biotechnology
Genomics
Management
Molecular Biology
Start Ups
Cell Culture
Life Sciences
Project Management
Medical Devices
Clinical Development
Genetics
Laboratory
Assay Development
Clinical Research
Stem Cells
Biochemistry
Lifesciences
Cell
Research
Oncology
Cell Biology
Immunology
Strategic Planning
Drug Discovery
Budgets
Cancer Research
Healthcare
Science
Product Development
Cancer
Fundraising
Fda
Medicine
Time Management
Pcr
Laboratory Skills
Proposal Writing
Quality Assurance
Technology Transfer
Western Blotting
U.s. Food and Drug Administration
Languages:
English
French
Certifications:
Tissue Bank Specialist
Christian Beaudry Photo 3

Project Manager

View page
Location:
1627 west Burnside Trl, Phoenix, AZ 85085
Industry:
Pharmaceuticals
Work:
Tgen
Project Manager
Skills:
Security Engineering
Christian Beaudry Photo 4

Christian Beaudry

View page

Publications

Us Patents

Cell Migration Inhibiting Compositions And Methods And Compositions For Treating Cancer

View page
US Patent:
7700615, Apr 20, 2010
Filed:
Feb 1, 2006
Appl. No.:
11/345132
Inventors:
David L. Edwards - Scottsdale AZ, US
Michael E. Berens - Gilbert AZ, US
Christian Beaudry - Scottsdale AZ, US
Assignee:
Avolix Pharmaceuticals, Inc. - Scottsdale AZ
International Classification:
A61K 31/47
A61K 31/45
US Classification:
514294, 514741, 514740, 514751
Abstract:
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.

Cell Migration Inhibiting Compositions And Methods And Compositions For Treating Cancer

View page
US Patent:
7012100, Mar 14, 2006
Filed:
Jun 4, 2002
Appl. No.:
10/161843
Inventors:
David L. Edwards - Scottsdale AZ, US
Michael E. Berens - Gilbert AZ, US
Christian Beaudry - Scottsdale AZ, US
Assignee:
Avolix Pharmaceuticals, Inc. - Scottscale AZ
International Classification:
A01N 33/22
A01N 33/20
A01N 33/18
A01N 33/16
A01N 33/00
US Classification:
514741, 514740, 514751
Abstract:
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.

Method Of Treatment Utilizing An Acellular Amnion Derived Therapeutic Composition

View page
US Patent:
20160199417, Jul 14, 2016
Filed:
Sep 14, 2015
Appl. No.:
14/853889
Inventors:
- Phoenix AZ, US
Christian Beaudry - Phoenix AZ, US
Terrell Suddarth - Winchester TN, US
International Classification:
A61K 35/50
A61Q 19/00
A61K 8/98
A61K 9/00
A61K 9/06
Abstract:
Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.
Control profile
Christian B Beaudry from Phoenix, AZ, age ~52 Get Report